Skip to main
VRCA
VRCA logo

VRCA Stock Forecast & Price Target

VRCA Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 22%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Verrica Pharmaceuticals Inc. has demonstrated significant growth in the volume of dispensed applicator units, with a notable 29% increase in Q3 2024 compared to Q2 2024, and a sustained 12% growth in Q4 2024, reaching 8,654 units which translated to approximately $5.9 million in sales. The company's efforts to normalize inventory levels are expected to enhance the alignment between product availability and consumer demand, potentially boosting future sales performance. Additionally, despite recent cost restructuring and a downsized sales force, the upward trend in dispensed units suggests a resilient market demand that could benefit the company in the upcoming quarters.

Bears say

Verrica Pharmaceuticals faces significant challenges due to competition from cheaper treatment options available in the market, which could hinder product pricing and payor coverage for its treatments. The company reported a substantial loss of $16.2 million in the fourth quarter of 2024, raising concerns about its financial viability and the need for additional funding for operations and debt repayment. Furthermore, uncertainties surrounding the clinical trials of its product candidate, Ycanth, coupled with potential supply chain disruptions, add to the risks affecting its growth prospects and overall business stability.

VRCA has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 22% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verrica Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verrica Pharmaceuticals Inc (VRCA) Forecast

Analysts have given VRCA a Buy based on their latest research and market trends.

According to 9 analysts, VRCA has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verrica Pharmaceuticals Inc (VRCA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.